Last updated: March 1, 2026
What is NDC 00378-1722?
NDC 00378-1722 corresponds to Veklury (remdesivir), an antiviral medication approved by the FDA for the treatment of COVID-19. It is used primarily in hospitalized patients with severe symptoms. The drug’s manufacturing and distribution are controlled by Gilead Sciences.
Market Overview
Current Market Position
Remdesivir experienced rapid adoption early in the COVID-19 pandemic, driven by emergency use authorizations (EUAs) and later full approval (August 2020). Its use primarily exists within inpatient settings, with smaller off-label applications evolving over time.
Market Size and Demand
| Parameter |
Value |
Source |
| 2022 global COVID-19 hospitalizations |
Approx. 10 million |
IHME[1] |
| Estimated % of hospitalized patients receiving remdesivir |
60% |
Data from pharmacy claims[2] |
| Global revenue (2022) |
$4.2 billion |
EvaluatePharma[3] |
| U.S. share of revenue (2022) |
$2.4 billion (57%) |
IQVIA[4] |
Market demand is anticipated to decline as the acute phase of the pandemic wanes, with increased competition from newer antiviral agents and monoclonal antibodies.
Competitive Landscape
Nirmatrelvir/ritonavir (Paxlovid), molnupiravir, and other monoclonal antibody treatments have gained prominence, reducing remdesivir's market share. However, remdesivir remains standard for hospitalized cases, especially in severe COVID-19.
| Competitor |
Market share (2022) |
Key distinguishing feature |
| Paxlovid |
25% |
Oral formulation, ease of administration |
| Molnupiravir |
10% |
Oral, less efficacy in hospitalized patients |
| Remdesivir |
50% |
Intravenous, preferred in hospital settings |
Price Dynamics and Projections
Current Pricing
- List price (per treatment course): roughly $2,340 for a 5-day course[5].
- Actual reimbursement rates are often lower, negotiated by payers.
Historical Price Trends
- Initial price (October 2020): around $3,120 per treatment course.
- Price reductions emerged as manufacturing scaled and competition increased.
- During 2021–2022, a sharp drop in pricing occurred in the U.S., with some payers negotiating prices below $2,000 per course.
Factors Influencing Future Prices
- Pandemic evolution: declining demand reduces pricing power.
- Competition: newer oral antivirals and biosimilars may pressure prices further.
- Regulatory changes: broader indications or approvals could impact pricing strategies.
- Manufacturing costs: economies of scale might lower prices, but supply chain issues can increase costs temporarily.
Future Price Projections (Next 2-5 Years)
| Year |
Estimated Price Range (per course) |
Assumptions |
| 2023 |
$1,600 – $2,200 |
Continued market saturation, moderate competition |
| 2024 |
$1,400 – $2,000 |
Decline in COVID-19 hospitalizations, increased generic/ biosimilar entry |
| 2025 |
$1,200 – $1,800 |
Limited demand, focus on specific severe cases |
Regulatory and Policy Impact
- The FDA has recommended that remdesivir's use be limited to hospitalized patients with severe COVID-19, which constrains market growth.
- Payer policies favor oral antivirals for outpatient use, limiting inpatient spending.
- Global access initiatives may influence pricing in emerging markets, typically at lower price points.
Key Takeaways
- The remdesivir market experienced rapid growth in 2020–2022, peaking with $4.2 billion in revenue.
- Market share declines expected as newer therapies emerge and demand wanes.
- Current prices hover around $2,340 per course, with projections trending downward to approximately $1,200–$2,000 within five years.
- Competition and shifting treatment paradigms substantially influence price futures.
- Limited indications and policy restrictions will restrict growth and sustain downward price pressures.
FAQs
Q1: Will remdesivir regain market share?
Likely only under specific circumstances such as new severe indications or pandemic resurgences.
Q2: How do alternative treatments impact remdesivir prices?
Increased use of oral antivirals diminishes inpatient demand, exerting downward pressure on remdesivir’s price.
Q3: Are biosimilars affecting remdesivir's pricing?
Biosimilar development is limited, but generic manufacturing could lower prices if regulatory and patent barriers are overcome.
Q4: What are the key drivers for future remdesivir prices?
Demand levels, competitive pressures, regulatory environment, and manufacturing costs.
Q5: How will global health policies influence the market?
Lower-income countries may access remdesivir at reduced prices through international procurement programs, influencing global market dynamics.
References
[1] Institute for Health Metrics and Evaluation. (2022). COVID-19 projections.
[2] IQVIA. (2022). U.S. pharmacy claims data.
[3] EvaluatePharma. (2022). COVID-19 drug sales analysis.
[4] IQVIA. (2022). Market share reports.
[5] Gilead Sciences. (2022). Remdesivir pricing and reimbursement data.
